These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32451179)

  • 1. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    Kuusk T; Bex A
    Eur Urol; 2020 Oct; 78(4):630-631. PubMed ID: 32451179
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    D'Andrea D; Pradere B; Shariat SF
    Eur Urol; 2021 Jan; 79(1):163-164. PubMed ID: 32981804
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    Afferi L; Moschini M; Mattei A; Montorsi F; Briganti A; Cathelineau X; Sanchez-Salas R
    Eur Urol; 2020 Aug; 78(2):289-290. PubMed ID: 32359702
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma.
    Singla N; Margulis V;
    Eur Urol; 2021 Jan; 79(1):e28. PubMed ID: 33008662
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
    Shirotake S; Kikuchi E; Tanaka N; Matsumoto K; Miyazaki Y; Kobayashi H; Ide H; Obata J; Hoshino K; Kaneko G; Hagiwara M; Kosaka T; Kanao K; Kodaira K; Hara S; Oyama M; Momma T; Miyajima A; Nakagawa K; Hasegawa S; Nakajima Y; Oya M
    J Urol; 2015 Apr; 193(4):1122-8. PubMed ID: 25444957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
    Hellenthal NJ; Shariat SF; Margulis V; Karakiewicz PI; Roscigno M; Bolenz C; Remzi M; Weizer A; Zigeuner R; Bensalah K; Ng CK; Raman JD; Kikuchi E; Montorsi F; Oya M; Wood CG; Fernandez M; Evans CP; Koppie TM
    J Urol; 2009 Sep; 182(3):900-6. PubMed ID: 19616245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant chemotherapy in the treatment of urothelial carcinoma of the upper urinary tract].
    Pape L; Richter J; Dunst J
    Strahlenther Onkol; 2020 Sep; 196(9):837-840. PubMed ID: 32561938
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-containing Reverse Thermal Gel (OLYMPUS): An Open-label, Single-arm, Phase 3 Trial.
    Ourfali S; Colombel M
    Eur Urol; 2021 Jan; 79(1):162. PubMed ID: 32891427
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.
    Rink M; Robinson BD; Green DA; Cha EK; Hansen J; Comploj E; Margulis V; Raman JD; Ng CK; Remzi M; Bensalah K; Kabbani W; Haitel A; Rioux-Leclercq N; Guo CC; Chun FK; Kikuchi E; Kassouf W; Sircar K; Sun M; Sonpavde G; Lotan Y; Pycha A; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2012 Aug; 188(2):398-404. PubMed ID: 22698626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Postoperative Adjuvant Chemotherapy for Patients with pT3N0M0 Upper Tract Urothelial Carcinoma.
    Huang YC; Chen MF; Shi CS; Shindel AW; Huang CE; Pang ST; Chuang CK; Chen CS; Chang YH; Lin WY; Ho DR; Chin CC; Kuo YH; Wu CF
    J Urol; 2015 Aug; 194(2):323-9. PubMed ID: 25796114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W
    J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant topical treatment of upper urinary tract urothelial tumours.
    O'Donoghue JP; Crew JP
    BJU Int; 2004 Sep; 94(4):483-5. PubMed ID: 15329096
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
    Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M
    Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience.
    Michael M; Tannock IF; Czaykowski PM; Moore MJ
    Br J Urol; 1998 Sep; 82(3):366-72. PubMed ID: 9772872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
    Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the upper urinary tract].
    Gustin P; Yossi S; Lafont M; Peyraga G; Trémolières P; Rousseau D; Cellier P; Paumier A; Martin F; Chapet O; Mesgouez-Nebout N
    Cancer Radiother; 2015 Apr; 19(2):120-6. PubMed ID: 25770883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
    Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
    World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.
    Necchi A; Lo Vullo S; Mariani L; Moschini M; Hendricksen K; Rink M; Sosnowski R; Dobruch J; Raman JD; Wood CG; Margulis V; Roupret M; Briganti A; Montorsi F; Xylinas E; Shariat SF;
    BJU Int; 2018 Feb; 121(2):252-259. PubMed ID: 28940605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.